Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Type
(
1 selected
)
Type
Guidance (25)
Guidance programme
(
1 selected
)
Guidance programme
Technology appraisal guidance (25)
Apply filters
Showing 11 to 20 of 25
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell
lung cancer
after platinum-based chemoradiation [ID6223]
Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell
lung cancer
ID 6399
Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell
lung cancer
TS ID 11975
Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell
lung cancer
[ID6149]
Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell
lung cancer
[ID6365]
Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell
lung cancer
[ID3895]
Technology appraisal guidance
Repotrectinib for treating ROS1-positive advanced non-small-cell
lung cancer
TS ID 11851
Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell
lung cancer
ID 6436
Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell
lung cancer
[ID6346]
Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell
lung cancer
TS ID 11951
Technology appraisal guidance
Previous page
1
Current page
2
3
Page
2
of
3
Next page
Results per page
10
25
50
All
Back to top